SOPHiA GENETICS (NASDAQ:SOPH) Insider Philippe Menu Sells 5,000 Shares of Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock in a transaction on Monday, October 12th. The stock was sold at an average price of $7.26, for a total transaction of $36,300.00. Following the transaction, the insider directly owned 195,993 shares of the company’s stock, valued at $1,422,909.18. The trade was a 2.49% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Philippe Menu also recently made the following trade(s):

• On Monday, October 5th, Philippe Menu sold 7,394 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.13, for a total transaction of $60,113.22.
• On Tuesday, August 25th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $8.68, for a total transaction of $43,400.00.
• On Wednesday, August 12th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The shares were sold at an average price of $7.52, for a total transaction of $37,600.00.
• On Monday, July 27th, Philippe Menu sold 5,000 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.66, for a total transaction of $28,300.00.

SOPHiA GENETICS Trading Down 0.4%

Shares of SOPHiA GENETICS stock traded down $0.03 during trading on Wednesday, hitting $7.06. The stock had a trading volume of 376,763 shares, compared to its average volume of 310,258. SOPHiA GENETICS SA has a 12 month low of $3.75 and a 12 month high of $8.98. The company has a debt-to-equity ratio of 0.58, a current ratio of 2.69 and a quick ratio of 2.55. The firm’s fifty day simple moving average is $7.95 and its 200-day simple moving average is $6.20. The stock has a market cap of $592.26 million, a PE ratio of -6.14 and a beta of 0.95.

SOPHiA GENETICS (NASDAQ:SOPH) last issued its quarterly earnings results on Wednesday, August 5th. The company reported ($0.26) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.05). SOPHiA GENETICS had a negative net margin of 93.86% and a negative return on equity of 132.47%. The firm had revenue of $23.31 million for the quarter, compared to the consensus estimate of $21.72 million. As a group, sell-side analysts expect that SOPHiA GENETICS SA will post -0.77 EPS for the current fiscal year.

Institutional Investors Weigh In On SOPHiA GENETICS

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. AWM Investment Company Inc. purchased a new stake in SOPHiA GENETICS in the 2nd quarter valued at about $9,809,000. Principal Financial Group Inc. increased its position in shares of SOPHiA GENETICS by 0.7% during the first quarter. Principal Financial Group Inc. now owns 1,409,242 shares of the company’s stock worth $6,976,000 after acquiring an additional 9,800 shares during the period. Hodges Capital Management Inc. purchased a new position in shares of SOPHiA GENETICS during the first quarter worth approximately $2,157,000. Sei Investments Co. bought a new stake in shares of SOPHiA GENETICS during the first quarter valued at approximately $1,772,000. Finally, 1492 Capital Management LLC raised its stake in shares of SOPHiA GENETICS by 8.4% during the first quarter. 1492 Capital Management LLC now owns 225,751 shares of the company’s stock valued at $1,117,000 after acquiring an additional 17,406 shares in the last quarter. Institutional investors own 31.59% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of SOPHiA GENETICS in a report on Friday, July 17th. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of SOPHiA GENETICS in a report on Monday. Zacks Research raised SOPHiA GENETICS to a “hold” rating in a research report on Tuesday, July 21st. Finally, BTIG Research upped their price objective on SOPHiA GENETICS from $8.00 to $9.00 and gave the company a “buy” rating in a research report on Wednesday, August 5th. Three investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Hold” and an average price target of $10.00.

About SOPHiA GENETICS

SOPHiA GENETICS is a healthcare technology company that develops cloud-based data analytics solutions for the life sciences and healthcare industries. Its platform is designed to help organizations analyze and interpret complex genomic and multimodal data to support more informed clinical and research decisions.

The company’s principal offering, the SOPHiA DDM platform, combines data management, analytics and artificial intelligence capabilities. It supports applications including cancer genomics, hereditary disease analysis, reproductive health and other areas of precision medicine.